ProQR Therapeutics N.V. - Ordinary Shares (PRQR): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRQR POWR Grades
- Sentiment is the dimension where PRQR ranks best; there it ranks ahead of 84.94% of US stocks.
- PRQR's strongest trending metric is Value; it's been moving up over the last 163 days.
- PRQR's current lowest rank is in the Momentum metric (where it is better than 9.38% of US stocks).
PRQR Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for PRQR is 0.02 -- better than merely 8.19% of US stocks.
- PRQR's price/sales ratio is 161.23; that's higher than the P/S ratio of 98.2% of US stocks.
- Revenue growth over the past 12 months for ProQR Therapeutics NV comes in at -77.63%, a number that bests just 1.94% of the US stocks we're tracking.
- Stocks that are quantitatively similar to PRQR, based on their financial statements, market capitalization, and price volatility, are CYTK, GLYC, CDAK, SGMO, and CRIS.
- PRQR's SEC filings can be seen here. And to visit ProQR Therapeutics NV's official web site, go to www.proqr.com.
PRQR Stock Price Chart Interactive Chart >
PRQR Price/Volume Stats
|Current price||$5.07||52-week high||$9.46|
|Prev. close||$5.27||52-week low||$4.13|
|Day high||$5.33||Avg. volume||524,399|
|50-day MA||$7.16||Dividend yield||N/A|
|200-day MA||$6.87||Market Cap||254.54M|
ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Company Bio
ProQR Therapeutics is a biopharmaceutical company, focused on RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. The company was founded in 2012 and is based in Leiden, the Netherlands.
Most Popular Stories View All
PRQR Latest News Stream
|Loading, please wait...|
PRQR Latest Social Stream
View Full PRQR Social Stream
Latest PRQR News From Around the Web
Below are the latest news stories about ProQR Therapeutics NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
Top-line data now expected to be announced in Q1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that the last patient completed their last vis
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended its convertible debt financing agreement entered into in 2020 with Kreos Capital (“Kreos”) and Pontifax Medison Debt Financing (“Pontifax”). The amended agreement provides ProQR with access to up to an additional $90 million
ProQR Therapeutics N.V. (NASDAQ:PRQR) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.14% to the previous days close as strong demand from buyers drove the stock to $7.43. Actively observing the price movement in the last trading, the stock closed the session at $7.00, falling within a range of $6.75 Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now? Read More »
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on ProQR (PRQR – Research Report) today and set a price target of $31.00. The company's shares closed last Thursday at $7.00. According to TipRanks.com, Wolleben is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 28.6% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals. Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $23.80.
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.
PRQR Price Returns